We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Cannabinoid Receptor Stimulator Reverses Symptoms of Alzheimer's Disease in Animal Model

By LabMedica International staff writers
Posted on 12 Sep 2012
Print article
A candidate drug that stimulates the activity of cannabinoid type 2 (CB2) receptors in the brain have been shown to reverse the symptoms of Alzheimer's disease in a rodent model.

The drug, 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7), lacks psychoactivity. In a paper published in the July 16, 2012, online edition of the journal Neurobiology of Aging investigators at the Cleveland Clinic (OH, USA) presented results obtained by treating a rat model of Alzheimer's disease with MDA7. Alzheimer's disease was induced in the animals by bilateral microinjection of amyloid-beta (A-beta) 1–40 fibrils into the hippocampal CA1 area of the rats' brains. The animals developed symptoms of a neuroinflammatory process, synaptic dysfunction, and cognitive impairment.

A group of the Alzheimer's rats was treated with intraperitoneal injections of MDA7 daily for 14 days. These animals showed decreased production of inflammatory cytokines and signaling molecules as well as restored cognition, memory, and synaptic plasticity.

"Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer's disease," said senior author Dr. Mohamed Naguib, professor of anesthesiology at the Cleveland Clinic. "Development of this compound as a potential drug for Alzheimer's would take many more years, but this is a promising finding worthy of further investigation."

Related Links:
Cleveland Clinic



New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
New
Preterm Delivery Test (phIGFBP-1)
Actim Partus 1ngeni
New
SARS-CoV-2 PCR Assay
AppliedBiosystems TaqCheck SARS-CoV-2 Fast PCR Assay Kit
New
Molecular Diagnostics Integrated System
SENTiNAT 200

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Representation of the molecular structure of the cathepsin B (catB) protein (Photo courtesy of Wikimedia Commons)

An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood

A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma. Cathepsin B (catB) is a lysosomal cysteine... Read more

Industry

view channel
Illustration

Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases

Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.